Repurposing the H.Pylori vaccine CTB-UE into a pulmonary arterial hypertension (PAH) vaccine: CTB-UE, a Helicobacter Pyroli vaccine, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 20/July/2018, 1.22 pm

Flu vaccine for normalizing blood sugar levels: Influenza A/Flu (H1N1) vaccine-based therapy for blood sugar disease: Influenza A/Flu (H1N1) vaccine increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 20/July/2018, 9.39 am
July 20, 2018
Antiviral therapy for Neuroinvasive West Nile virus: β-(1,3)-glucan/Lentinan(LNT), isolated from mushroom Lentinus edodes, increases the expression of RIPK3, promotes chemokines production, inhibits neuroinflammation, and restricts neuroinvasive West Nile virus production and pathogenesis in neurons via upregulation of its target gene, 20/July/2018, 1.51 pm
July 20, 2018
Show all

What they say: 

A study from the University of California, La Jolla, California, USA shows that Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November  2009 issue of the journalNature Medicine[the number 1 journal in General Medicine with an I.F of 28.054],  by Prof. Thistlethwaite PA, Li X and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Repurposing the H.Pyroli vaccine CTB-UE into a pulmonary arterial hypertension (PAH): CTB-UE, a Helicobacter Pyroli vaccine, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3


The significance of the study:  

This study suggests, first the first time, Helicobacter Pyroli vaccine CTB-UE-based therapy, with detailed mechanistic insights, for curing pulmonary arterial hypertension.

CTB-UE vaccine, which contains mucosal adjuvant cholera toxin B subunit (CTB) and five cell epitopes from the H. pylori urease subunits,, has been shown to be effective in controlling infections caused by H. pylori. However, the mechanism of action remains largely unknown.

H.Pyroli vaccine CTB-UEby increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1).  Thus, H.Pyroli CTB-UE vaccineeither alone or in combination with other drugs,” may be used to treat/cure pulmonary arterial hypertension (Fig. 2). Together, this study suggests that by vaccinating pulmonary hypertensive patients with H.Pyroli vaccine CTB-UEone may prevent pulmonary arterial hypertension

Figure 1. Mechanistic insights into how H.Pyroli vaccine CTB-UE functions as an anti-pulmonary arterial hypertensive vaccine.  H.Pyroli CTB-UE vaccine may promote insulin sensitivity and protect against myocardial infarction, via up-regulation of reprogramming protein Lin-28

Figure 2.   H.Pyroli vaccine CTB-UE  may function as an anti-hyperglycemic agent through induction of Lin-28

 


Details of the research findings: 

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Undisclosed mechanistic information: How  H.Pyroli CTB-UE vaccine  decreases the expression of Notch3 and its target gene

Amount: $500#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,  Repurposing the H.Pyroli vaccine CTB-UE into a pulmonary arterial hypertension (PAH) vaccine: CTB-UE, a Helicobacter Pyroli vaccine, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 20/July/2018, 1.22 pm,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite us, drop us a line at info@genomediscovery.org

Comments are closed.